Mesolimbic dopaminergic decline after cannabinoid withdrawal.
about
Pharmacotherapy for cannabis dependence: how close are we?Addicted to palatable foods: comparing the neurobiology of Bulimia Nervosa to that of drug addictionInvolvement of dopamine D2 receptors in addictive-like behaviour for acetaldehydeEvaluation of sex differences in cannabinoid dependence.Noradrenergic transmission in the extended amygdala: role in increased drug-seeking and relapse during protracted drug abstinenceThe circumplex model of affect: an integrative approach to affective neuroscience, cognitive development, and psychopathologyWithdrawal from THC during adolescence: sex differences in locomotor activity and anxiety.Persistent and reversible morphine withdrawal-induced morphological changes in the nucleus accumbens.Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues.Longitudinal predictors of cannabis use and dependence in offspring from families at ultra high risk for alcohol dependence and in control families.Intermediate cannabis dependence phenotypes and the FAAH C385A variant: an exploratory analysisAbnormal cerebellar morphometry in abstinent adolescent marijuana usersMarijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes.Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signsHampered long-term depression and thin spine loss in the nucleus accumbens of ethanol-dependent ratsDevelopment and consequences of cannabis dependence.Cannabis and the brain.Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeysDrug dependence as a disorder of neural plasticity: focus on dopamine and glutamate.Endocannabinoids and exercise.Endocannabinoid 2-Arachidonoylglycerol Self-Administration by Sprague-Dawley Rats and Stimulation of in vivo Dopamine Transmission in the Nucleus Accumbens Shell.Cannabinoid modulation of drug reward and the implications of marijuana legalizationChronic stress, drug use, and vulnerability to addiction.CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the ratPharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications.Decreased cocaine motor sensitization and self-administration in mice overexpressing cannabinoid CB₂ receptors.Self-administration of cannabinoids by experimental animals and human marijuana smokers.Chronic Δ⁹-tetrahydrocannabinol exposure induces a sensitization of dopamine D₂/₃ receptors in the mesoaccumbens and nigrostriatal systems.The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis usersMarijuana dependence: not just smoke and mirrors.Prefrontal cortex morphometry in abstinent adolescent marijuana users: subtle gender effects.Agonism of the endocannabinoid system modulates binge-like alcohol intake in male C57BL/6J mice: involvement of the posterior ventral tegmental area.The effects of Δ9-tetrahydrocannabinol on the dopamine system.Basic neuroanatomy and neuropharmacology of cannabinoids.Potential programming of dopaminergic circuits by early life stress.Cannabinoids for the treatment of schizophrenia? A balanced neurochemical framework for both adverse and therapeutic effects of cannabis use.Structural plasticity in mesencephalic dopaminergic neurons produced by drugs of abuse: critical role of BDNF and dopamine.The dopamine hypothesis of drug addiction and its potential therapeutic value.The addicted brain.Altered Mesolimbic Dopamine System in THC Dependence.
P2860
Q24648976-D8016118-557B-4FE6-94A3-98ABDCE5EB22Q26996271-C75D083D-0220-48F7-ABC1-7B06B72ACE7FQ28539688-BB117280-64BA-4CA0-BED2-10D5DDD30CACQ30415208-386CA638-8B16-4BA8-8D5A-7692FB0DF7D6Q30455336-57C554A0-C5D2-421E-93DD-287E5A5EA77CQ30494504-0EC4C17E-1373-42F6-98A7-5AEEF80D95EDQ30596478-11CC488D-F7A2-4F3D-8CE8-955C654B7AD2Q33263616-C5DBE8E7-7394-46DA-82D7-04B9281E969FQ33645739-8C2E0BA4-564A-4376-AA67-2EED8DF56929Q33727978-70507CC2-5FCB-4F94-BB26-A8F7673B97C7Q33824425-4183FEF3-9027-4AA7-95A3-8F13D861D37DQ33838292-8244E22C-C262-4E79-BE01-448D206365D7Q33865218-AA2D91AC-5C7D-49D0-A8A7-ED5B5C55D413Q34028114-42C69AB0-A0B1-47C3-A621-C224C274ED94Q34144592-3E7FA45E-CE0E-4BD8-9EF4-C60F95B77CE2Q34157382-84615A69-FDA3-4240-8960-2EBF48E35A7AQ34199483-16B9E9EB-132B-4B4C-866F-520C0DCA7AAEQ34257459-9F14C933-33EC-44C4-93A6-136ACF17DCF0Q34273699-EABB3D54-4271-4F59-B84F-F5E494BCF730Q34351200-0EB6422E-90DA-4932-86C7-4D336297ECFCQ34359778-5ED9DA05-CD66-4BF2-8353-BCADF1312E30Q34451442-72C33C02-D3B1-4105-9AD9-D20A48A4D9BEQ34875333-BFDE38BB-761D-4D31-82CD-EDCD39B78DC5Q35047694-04455FC4-EC03-4EA8-A45F-00E30CC458D9Q35576598-B8AE6A4C-5060-4D0F-A058-8ABCCE21AE7FQ35982290-30315EED-661F-4CEA-ACE7-C6E7E0BD4908Q36149174-518F231D-D1F3-4E3F-B5E8-AAC0DA63D437Q36234294-428A51D7-D757-4C44-A335-4721798CC6A0Q36536527-14780EF1-62B2-40CD-918C-2B19C90A656BQ36712200-DE187B87-5B30-44BC-8B40-1F6522BB05AFQ37341421-AB591E32-03C7-4B5A-8524-E6C112D8E920Q37387731-9BFEAD84-72CE-4749-8AD6-D412975534C3Q37441554-B486EF9E-CCA3-48CB-8FBD-FA677399D78CQ37444802-D2F920AB-D87D-47D8-8201-354E47D97D89Q37810812-74F17E10-DB0B-4441-B803-8BDD8FAB5AF8Q38039423-DD3FEA3C-A36A-4134-9633-E0AC3D6E1825Q38287920-6309F6A6-5DFC-4B07-BCE0-48E0E2705013Q39431132-0040DE85-3AA8-4C7D-8805-7FB193DD4695Q41364925-6F678B0E-B743-466C-B72F-5BC969377F16Q41760767-9993E4A3-5198-4044-9B38-6B9C56E5F16D
P2860
Mesolimbic dopaminergic decline after cannabinoid withdrawal.
description
1998 nî lūn-bûn
@nan
1998 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Mesolimbic dopaminergic decline after cannabinoid withdrawal.
@ast
Mesolimbic dopaminergic decline after cannabinoid withdrawal.
@en
Mesolimbic dopaminergic decline after cannabinoid withdrawal.
@nl
type
label
Mesolimbic dopaminergic decline after cannabinoid withdrawal.
@ast
Mesolimbic dopaminergic decline after cannabinoid withdrawal.
@en
Mesolimbic dopaminergic decline after cannabinoid withdrawal.
@nl
prefLabel
Mesolimbic dopaminergic decline after cannabinoid withdrawal.
@ast
Mesolimbic dopaminergic decline after cannabinoid withdrawal.
@en
Mesolimbic dopaminergic decline after cannabinoid withdrawal.
@nl
P2093
P2860
P356
P1476
Mesolimbic dopaminergic decline after cannabinoid withdrawal.
@en
P2093
P2860
P304
10269-10273
P356
10.1073/PNAS.95.17.10269
P407
P577
1998-08-01T00:00:00Z